Chugai's Pipeline Rebirth: Allosteric ALK and AQUA07 Take Center Stage

A Record First Half

Chugai Pharmaceutical delivered a blockbuster H1 FY2026, with revenue rising 14.7% year-on-year to ¥663.3 billion and core operating profit up 21% to ¥329.1 billion. As CEO Okuda noted, “Both our financial performance and business activities progressed steadily during the first half.” — Osamu Okuda, President and CEO · 2026-07-24 The growth was broad-based: domestic sales grew 6.5%, overseas sales jumped 14.1% on strong Hemlibra exports, and other revenue surged ¥29.8 billion thanks to royalty income from Galderma partners NEMLUVIO and Foundayo. NEMLUVIO, already a cash cow, saw global sales of $433 million in H1, while Foundayo (orforglipron) began contributing royalty income after its April U.S. launch for obesity. This is a notable shift from the export-driven model of prior years—Vabysmo and Hemlibra still carry the top line, but the royalty stream is becoming a meaningful second engine.

AQUA07: A New Modality in Oncology

The pipeline highlight is AQUA07, an allosteric ALK inhibitor built on Chugai's proprietary macrocyclic peptide platform. In the prepared remarks, Project Lifecycle Management head Kusano explained its differentiated mechanism: “AQUA07 binds not to the ATP pocket, but to the allosteric site indicated by B in the diagram through a binding mode unique to macrocyclic peptides.” — Kusano, Head of the Project Lifecycle Management unit · 2026-07-24 The FDA granted fast track designation in May, and the first patient was dosed in a Phase I study for ALK-positive non-small cell lung cancer. Management sees potential both as a monotherapy in resistant patients and as first-line combination therapy with existing TKIs, aiming to extend PFS and suppress resistance mechanisms. This is a fresh company-unique theme—ALK inhibitor was already a recurring keyword, but the allosteric angle and macrocyclic peptide linkage are genuinely new.

For the first line, the combination treatment is considered... If we combine them together, those treatments, the emergence of the resistance change can be actually suppressed. So compared to the existing drug, PFS will be longer.

Beyond AQUA07, the pipeline is accelerating: NXT007 entered two Phase III studies in hemophilia A, and PiaSky showed strong complete remission rates in aHUS, positioning for global filings. Celiac disease candidate DONQ52 entered Phase IIa, with management emphasizing the go/no-go discipline that has cut cycle times. This stands in contrast to prior quarters, where the focus was on mid-size molecules and switch antibodies—now the narrative has pivoted to macrocyclic peptides and allosteric inhibition.

Strategic Investment: Redefining Capital Allocation

Perhaps the most consequential move is the creation of a strategic investment department, announced alongside the dividend hike (an increase for the 10th consecutive year). In the Q&A, CEO Okuda explained the rationale: “By conducting M&A, we acquire technology and then combining this new technology with our in-house technology, we could provide something new.” — Osamu Okuda, President and CEO · 2026-07-24 This is a deliberate evolution from organic R&D and open innovation toward active capital deployment, leveraging the ¥962.6 billion net cash balance. Management sees M&A, in-licensing, and co-development as levers to accelerate growth, potentially expanding beyond pharma's traditional boundaries. The strategic pivot echoes prior commentary—as early as the 2025-07-24 call, Kusano mentioned “NXT007, we are developing a device for easy administration” — Tsukasa Kusano, Head of Project Lifecycle Management Unit · 2025-07-24—but the new department formalizes a more aggressive capital allocation posture. The market has responded cautiously, with the stock holding steady, but the strategic shift could reshape Chugai's long-term growth trajectory.

Overall, Chugai is transitioning from a reliable exporter of Hemlibra and other Roche-partnered drugs to a self-driven innovator with a richer pipeline and a willingness to spend. The company's unique themes—small cell lung cancer, allosteric inhibition, and strategic investment—are not riding a global wave; they are distinct, company-specific bets. With record earnings and a clear capital allocation framework, Chugai is positioning for a more diversified and internally generated future.